TTRX
Turn Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
9.46
▼ 0.08 (0.84%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.31
Prev close
9.54
Day high
9.93
Day low
9.35
Volume
22.23K
Market cap
$287.28M
P/E (TTM)
—
52W range
2.57 – 26.50
Day trading desk
Gap from prior close
-2.41%
Prior close 9.54
VWAP
9.59
-1.35% from price
Relative volume
0.27×
Quiet session
Session range
6.61%
9.31 – 9.93
Position in range
24%
Near session low
ATR (14D)
0.83
8.76% of price
Prior day high
10.03
PDH
Prior day low
9.52
PDL
Bid / ask spread
—
Quote not published
Session volume
22.23K
Avg 81.26K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.15%
+0.2%
1M
-0.21%
-3.9%
3M
+90.34%
+87.2%
6M
+171.06%
+160.0%
YTD
+140.10%
+127.8%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TTRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
15.74M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 28, 26 | BURNAM BRADLEY EVAN Chief Executive Officer |
STOCK | 600.00K | $0 | Indirect |
| Apr 2, 26 | BURNAM BRADLEY EVAN Chief Executive Officer |
STOCK | 300.00K | $0 | Indirect |
| Jan 7, 26 | DEWHURST MARTIN WILLIAM Director |
STOCK | 21.88K | $0 | Direct |
| Dec 12, 25 | CHAUDHARY ZURAIZ Chief Financial Officer |
BUY | 2.50K | $8.75K | Direct |
| Nov 24, 25 | GOLDEN ARTHUR F Director |
BUY | 9.87K | $33.95K | Direct |
| Nov 21, 25 | GOLDEN ARTHUR F Director |
BUY | 20.53K | $58.93K | Direct |
| Nov 21, 25 | CHAUDHARY ZURAIZ Chief Financial Officer |
BUY | 2.45K | $7.07K | Direct |
| Nov 17, 25 | CHAUDHARY ZURAIZ Chief Financial Officer |
BUY | 2.50K | $9.05K | Direct |
| Oct 23, 25 | GOLDEN ARTHUR F Director |
BUY | 20.20K | $100.00K | Direct |
| Oct 23, 25 | CHAUDHARY ZURAIZ Chief Financial Officer |
BUY | 5.05K | $25.00K | Direct |
| Oct 23, 25 | CHESED ABRAHAM Unknown |
BUY | 14.29K | $65.72K | Indirect |
| Oct 8, 25 | GOLDEN ARTHUR F Director |
STOCK | 10.00K | $0 | Direct |
| Oct 8, 25 | GENGOS ANDREW Director |
STOCK | 10.00K | $0 | Direct |
| Oct 8, 25 | KESTER KENT EDWARD Director |
STOCK | 10.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BURNAM BRADLEY EVAN |
Chief Executive Officer | — | Stock Gift |
CHAUDHARY ZURAIZ |
Chief Financial Officer | 12.50K | Purchase |
CHESED ABRAHAM |
Unknown | — | Purchase |
DEWHURST MARTIN WILLIAM |
Director | 21.88K | Stock Award(Grant) |
GENGOS ANDREW |
Director | 10.00K | Stock Award(Grant) |
GHODADRA NEILESH SHAILESH |
Officer and Director | 10.00K | Stock Award(Grant) |
GOLDEN ARTHUR F |
Director | 60.60K | Purchase |
KESTER KENT EDWARD |
Director | 10.00K | Stock Award(Grant) |
Fundamentals
Market cap$287.28M
Enterprise value$277.63M
Revenue (TTM)—
Gross profit$-1.61M
EBITDA$-8.51M
Net income$-8.45M
EPS (TTM)$-0.28
Free cash flow$4.17M
Total cash$10.29M
Total debt$6.12M
Book value / share$0.21
Shares outstanding30.37M
Float10.83M
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-63.07
PEG ratio—
Price / sales—
Price / book46.15
EV / revenue—
EV / EBITDA-32.64
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-686.28%
Return on assets-50.27%
Debt / equity891.13
Current ratio1.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | — |
| Research & development | $265.57K | $245.96K | $7.50K | +8.0% |
| Selling, general & admin | $5.59M | $1.55M | $2.30M | +260.6% |
| Total operating expense | $5.86M | $1.80M | $2.31M | +226.0% |
| Operating income | -$5.86M | -$1.80M | -$2.31M | -226.0% |
| Net interest income | -$467.37K | $28.71K | $15.88K | -1,727.9% |
| Pre-tax income | -$3.19M | -$1.77M | -$2.29M | -80.6% |
| Net income | -$3.19M | -$1.77M | -$2.29M | -80.6% |
| Net income to common | -$3.19M | -$1.77M | -$2.29M | -80.6% |
| Basic EPS | -0.12 | -0.06 | -0.08 | -99.8% |
| Diluted EPS | -0.12 | -0.06 | -0.08 | -99.8% |
| EBIT | -$5.86M | -$1.80M | -$2.31M | -226.0% |
| EBITDA | -$5.81M | -$1.75M | -$2.26M | -231.8% |
| Basic shares | 27.72M | 29.45M | 29.45M | -5.9% |
| Diluted shares | 27.72M | 29.45M | 29.45M | -5.9% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $5.08M | $872.60K | $1.18M | +481.7% |
| Cash & short-term investments | $5.08M | $872.60K | $1.18M | +481.7% |
| Total current assets | $5.20M | $1.10M | $1.20M | +373.3% |
| Property, plant & equipment | $78.62K | $120.45K | $33.22K | -34.7% |
| Goodwill & intangibles | $922.17K | $821.93K | $769.94K | +12.2% |
| Total assets | $12.16M | $2.05M | $2.01M | +493.6% |
| Total current liabilities | $6.00M | $707.93K | $489.78K | +748.0% |
| Total debt | $80.38K | $121.04K | $25.16K | -33.6% |
| Total liabilities | $7.48M | $2.23M | $1.93M | +235.8% |
| Retained earnings | -$22.39M | -$19.20M | -$17.43M | -16.6% |
| Shareholder equity | $4.69M | -$177.43K | $85.77K | +2,741.4% |
| Working capital | -$806.98K | $389.99K | $712.04K | -306.9% |
| Net tangible assets | $3.76M | -$999.36K | -$684.17K | +476.7% |
| Shares issued | 29.45M | 29.45M | 29.45M | 0.0% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Net income | -$3.19M | -$1.77M | -$2.29M | -80.6% |
| Depreciation & amortisation | $52.75K | $47.48K | $43.92K | +11.1% |
| Stock-based compensation | $669.25K | $352.83K | $640.26K | +89.7% |
| Change in working capital | $2.37M | -$1.86K | $229.74K | +127,604.4% |
| Operating cash flow | -$2.56M | -$1.36M | -$1.38M | -88.3% |
| Capital expenditure | -$152.99K | -$99.47K | -$44.31K | -53.8% |
| Investing cash flow | -$152.99K | -$99.47K | -$44.31K | -53.8% |
| Financing cash flow | $6.92M | $1.15M | $500.00K | +500.4% |
| Free cash flow | -$2.72M | -$1.46M | -$1.42M | -85.9% |
| End cash position | $5.08M | $872.60K | $1.18M | +481.7% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Basic EPS | -0.03 | -0.06 | -0.04 | -0.01 | +53.6% |
| Diluted EPS | -0.03 | -0.06 | -0.04 | -0.01 | +53.6% |
| Basic shares | 29.48M | 29.45M | 29.45M | 29.45M | +0.1% |
| Diluted shares | 29.48M | 29.45M | 29.45M | 29.45M | +0.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.02 | -0.20 | -900.0% |
| Mar 2026 | -0.02 | -0.04 | -102.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 1 | $0 | — |
| Next quarter | -0.08 | 1 | $0 | — |
| Current year | -0.40 | 1 | $0 | 0.0% |
| Next year | -0.39 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$26.00
High target$26.00
Low target$26.00
Implied upside174.84%
Analyst count1
ConsensusSTRONG BUY
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders52.85%
Held by institutions3.79%
Institutions holding31
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.85
-3.97% from price
SMA 20
9.29
+1.81% from price
SMA 50
8.43
+12.20% from price
SMA 100
6.31
+50.02% from price
SMA 200
5.03
+88.21% from price
EMA 12
9.65
-2.01% from price
EMA 26
9.27
+2.02% from price
EMA 50
8.42
+12.35% from price
RSI (14)
52.3
Neutral
MACD (12,26,9)
0.38
Hist -0.09
ATR (14)
0.83
8.76% of price
Realised vol 30D
83.9%
Annualised
Bollinger upper
11.08
20, 2σ
Bollinger lower
7.50
20, 2σ
50 / 200 cross
Golden
8.43 vs 5.03
Trend bias
Above 200
+88.21%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.51
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
83.9%
Annualised
Market vol 1Y
13.5%
SPY, annualised
Max drawdown 1Y
-70.5%
Peak to trough
Max drawdown 5Y
-70.5%
Peak to trough
ATR 14
0.83
8.76% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
57.73K
Prior 38.51K
Change vs prior
+49.9%
Shorts adding
% of float
—
—
% of shares out
0.28%
Against total outstanding
Days to cover
0.7
Liquid
Float
10.83M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 20, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 29, 25 | D. Boral Capital | INITIATED | — | Buy |
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-18
Corporate Changes & Voting Matters
8-K · 2026-08-17
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-07
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-27
Headlines
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Business Wire · 3d ago
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Business Wire · 11d ago
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Business Wire · 26d ago
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
MarketBeat · 43d ago
Turn Therapeutics’ stock jumps on AD data and trial expansion
Clinical Trials Arena · 46d ago
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis
MT Newswires · 47d ago
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Business Wire · 47d ago
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Business Wire · 48d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.